CA2438030A1 - Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators - Google Patents

Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators Download PDF

Info

Publication number
CA2438030A1
CA2438030A1 CA002438030A CA2438030A CA2438030A1 CA 2438030 A1 CA2438030 A1 CA 2438030A1 CA 002438030 A CA002438030 A CA 002438030A CA 2438030 A CA2438030 A CA 2438030A CA 2438030 A1 CA2438030 A1 CA 2438030A1
Authority
CA
Canada
Prior art keywords
angiogenesis
protein
sequence
nucleic acid
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438030A
Other languages
English (en)
French (fr)
Inventor
Richard Murray
Richard Glynne
Susan R. Watson
Natasha Aziz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438030A1 publication Critical patent/CA2438030A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002438030A 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators Abandoned CA2438030A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US78435601A 2001-02-14 2001-02-14
US09/784,356 2001-02-14
US79139001A 2001-02-22 2001-02-22
US09/791,390 2001-02-22
US28547501P 2001-04-19 2001-04-19
US60/285,475 2001-04-19
US31002501P 2001-08-03 2001-08-03
US60/310,025 2001-08-03
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33424401P 2001-11-29 2001-11-29
US60/334,244 2001-11-29
PCT/US2002/004915 WO2002079492A2 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Publications (1)

Publication Number Publication Date
CA2438030A1 true CA2438030A1 (en) 2002-10-10

Family

ID=27559580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438030A Abandoned CA2438030A1 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Country Status (5)

Country Link
EP (1) EP1418943A1 (de)
JP (1) JP2004531249A (de)
AU (1) AU2002257004A1 (de)
CA (1) CA2438030A1 (de)
WO (1) WO2002079492A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2002062945A2 (en) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
US7622443B2 (en) 2002-04-26 2009-11-24 California Institute Of Technology Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
WO2004091383A2 (en) 2003-04-01 2004-10-28 Genzyme Corporation Breast endothelial cell expression patterns
EP1619499B1 (de) 2003-04-25 2011-01-05 Takeda Pharmaceutical Company Limited Neues screening-verfahren
US7267950B2 (en) * 2003-05-01 2007-09-11 Veridex, Lcc Rapid extraction of RNA from cells and tissues
US9309323B2 (en) 2003-06-09 2016-04-12 The University Of British Columbia Methods for detecting and treating cancer
US7833733B2 (en) 2003-06-09 2010-11-16 The University Of British Columbia Methods for detecting and treating cancer
EP1642137A2 (de) * 2003-06-30 2006-04-05 Genova Ltd. Mit kardiovaskulären erfrankungen assoziierte sekretierte polypeptide
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
DE10340373A1 (de) * 2003-08-30 2005-03-24 Henkel Kgaa Verfahren zur Bestimmung von Haarzyklus-Marken
JP2005073621A (ja) * 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
WO2005069855A2 (en) * 2004-01-13 2005-08-04 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
DK1755659T3 (da) 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
WO2005103283A1 (ja) 2004-04-23 2005-11-03 Takeda Pharmaceutical Company Limited 新規スクリーニング方法
WO2005113788A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
ATE543914T1 (de) * 2005-09-01 2012-02-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
JP2009526861A (ja) * 2006-02-14 2009-07-23 ゲイシンガー クリニック 血管新生標的としてのｇｐｃｒ
AU2007218158A1 (en) * 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
ES2544957T3 (es) 2006-03-21 2015-09-07 Genentech, Inc. Terapia combinada que implica antagonistas alfa5beta1
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US20100255518A1 (en) 2006-04-04 2010-10-07 Goix Philippe J Highly sensitive system and methods for analysis of troponin
WO2009017833A2 (en) 2007-08-02 2009-02-05 Arresto Biosciences Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2216399A1 (de) * 2009-01-30 2010-08-11 Université de la Méditerranée Humanes, lösliches CD146, Herstellung und Verwendungen
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
JP5868176B2 (ja) 2009-07-08 2016-02-24 株式会社ＡＣＴＧｅｎ 抗癌活性を有する抗体
SG178845A1 (en) 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
EP2473529B1 (de) * 2009-09-03 2016-02-10 Cancer Research Technology Limited Clec14a inhibitoren

Also Published As

Publication number Publication date
WO2002079492A2 (en) 2002-10-10
JP2004531249A (ja) 2004-10-14
AU2002257004A1 (en) 2002-10-15
WO2002079492A8 (en) 2004-03-25
EP1418943A1 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
CA2438030A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US7435589B2 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US6682890B2 (en) Methods of diagnosing and determining prognosis of colorectal cancer
CA2459219A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
CA2477043A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
CA2453098A1 (en) Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030124579A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040253606A1 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20030232350A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2451465A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2444691A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20100297152A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2425569A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20070059748A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2440703A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
CA2381699A1 (en) Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
WO2002055988A2 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US6455668B1 (en) Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20030108926A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20030157544A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2003081250A1 (en) Novel compositions and methods in cancer associated with altered expression of prlr
CA2431313A1 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
CA2479719A1 (en) Novel compositions and methods in cancer associated with altered expression of mcm3ap

Legal Events

Date Code Title Description
FZDE Discontinued